Abstract 1674P
Background
Following the NAPOLI-1 trial, pegylated liposomal irinotecan (nal-IRI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) (nal-IRI + 5-FU/LV), is a standard treatment for advanced pancreatic ductal adenocarcinoma (PDAC) patients progressing after gemcitabine-based chemotherapy. The VILP registry captured real-world data on metastatic PDAC patients in Czech Republic receiving nal-IRI + 5-FU/LV.
Methods
Data were collected on all metastatic PDAC patients that received nal-IRI + 5-FU/LV, had an Eastern Cooperative Oncology Group performance status 0 or 1, and had progressed on gemcitabine-based chemotherapy, first line or (neo)adjuvant. Treatment was until progression or unmanageable toxicity. For the final evaluation of data, endpoints correspond to those published in the NAPOLI-1 trial; primary endpoint was overall survival (OS), calculated as the time from the treatment initiation to the date of death. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR) and treatment toxicity.
Results
As of April 6, 2023, 142 PDAC patients were enrolled, of which 129 were evaluable. Patients had a median age of 66 years, 95 (73.6%) received nal-IRI + 5-FU/LV as second line therapy and 101 (78.3%) had ECOG PS 1. A total of 93 (72.1%) patients discontinued treatment and median treatment duration was 2.3 months (range: 0.0-18.8) with the principal reason for discontinuation being disease progression (n=45, 48.4%). Median and 6-months OS were 10.1 months (95% CI 6.0–not reached) and 57.1% (95% CI 47.4–68.7), respectively. Median and 6-months PFS were 3.5 months (95% CI 3.1–5.7) and 35.5% (95% CI 27.1–46.6), respectively. ORR was 10.1% (12 cases of partial response and 1 complete response). A total of 19 adverse events (AEs) occurred in 17 (13.2%) patients, with the most frequent AEs being diarrhoea (n=9; grade 3 n=3) and fatigue (n=3; grade 3 n=1).
Conclusions
The VILP register confirms the effectiveness of nal-IRI + 5-FU/LV as a well-tolerated treatment option for patients with PDAC in real-world practice.
Clinical trial identification
Editorial acknowledgement
Editorial assistance was provided by Emily Eagles of Empowering Strategic Performance Ltd and supported by Servier Medical Affairs.
Legal entity responsible for the study
Servier.
Funding
Servier.
Disclosure
S. Batko: Financial Interests, Personal, Other, Honoraria: Amgen, Bristol Myers Squibb, Eli-Lilly, Ipsen, Merck, Pierre Fabre, Servier. T. Buchler: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Astellas, Janssen, Ipsen, Merck; Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Ipsen, Merck, Servier, Eli Lilly, Pfizer, Accord; Financial Interests, Institutional, Local PI: Bristol Myers Squibb, Merck, Bayer, Exelixis, Eisai, Eli Lilly, Roche, MSD; Financial Interests, Personal and Institutional, Coordinating PI: AstraZeneca; Non-Financial Interests, Advisory Role: Leram Pharmaceuticals. B. Melichar: Financial Interests, Personal, Advisory Board: Roche, BMS, MSD, Novartis, Merck, E. Lilly, Pfizer, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1589P - Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin
Presenter: Niels Guchelaar
Session: Poster session 22
1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Presenter: Berenice Freile
Session: Poster session 22
1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Presenter: Tamar Esakia
Session: Poster session 22
1617P - PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Poster session 22
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Alison Schram
Session: Poster session 22
1620P - A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Presenter: Davide Melisi
Session: Poster session 22
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Presenter: Shubham Pant
Session: Poster session 22
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Presenter: Shunsuke Kondo
Session: Poster session 22
1623P - Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Presenter: Dirk Arnold
Session: Poster session 22